**Supplement 1**

# A Prospective Study on the Use of Vitamin B3 Supplementation in Glaucoma

# Trial protocol – Version 1

# Date: 29May 2017

## Protocol synopsis

|  |  |
| --- | --- |
| **Title** | A prospective study on the use of vitamin B3 supplementation in glaucoma |
| **Objectives** | To determine whether vitamin B3 supplements in participants with glaucoma leads to short-term improvement in visual function measured using visual fields and the electroretinogram (ERG) |
| **Design** | Prospective, randomised, crossover, double-masked interventional study |
| **Outcomes** | Primary outcome measures: short-term changes in electroretinogram (ERG), and visual field sensitivity. |
| **Study duration** | Initial study for 6 months looking at short-term changes to the structure and function of the eye. Participants may be invited to have ongoing ERGs and imaging performed as part of their continued management in the Glaucoma Investigative Research Unit. |
| **Population** | Participants diagnosed and treated for glaucoma, over 18 years of age, not currently pregnant or breastfeeding or diagnosed with cancer in the last 5 years and able to provide written informed consent. |

## 

## Investigators and facilities

## *Study location*

Screening, study visits and ophthalmological investigations will be conducted at two sites, Eye and Ear on the Park (2 St Andrews Place, East Melbourne, VIC 3002) and Melbourne Eye Specialists (77 Victoria Parade, Fitzroy, VIC 3065).

## *Study management*

This investigator-initiated trial will be coordinated by a research team consisting of the principal investigator and associate researchers. The principal investigators or associate researchers will obtain informed consent and perform clinical assessments.

## *Sponsor*

This is an investigator-initiated trial.

## *Funding and resources*

A grant has been applied for with the Ophthalmic Research Institute Australia (ORIA). If the grant is unsuccessful, the Centre for Eye Research Australia (CERA) will provide the necessary funds to complete the study.

## Aim

To investigate whether nicotinamide leads to improved short-term functional gains in patients with early primary open angle glaucoma (POAG).

## Rationale

This will be the first clinical study to investigate the short-term effects in visual function using NAM. The crossover study design means that all participants will take NAM and placebo tablets (randomly assigned to take NAM or placebo first) for 12 weeks each. This study will inform us whether NAM can improve inner retinal functional over a short period (12 weeks) beyond what can be achieved with conventional IOP lowering using topical medication. This study will determine whether NAM supplements should subsequently be investigated in a large, randomised longitudinal clinical trial to determine whether short-term functional improvement with NAM can accurately predict long-term progression in glaucoma. NAM is potentially an easy and accessible intervention for people with glaucoma to revive and provide neuroprotection for their remaining RGCs.

Feasible designs that allow assessment of neuroprotection by means other than IOP lowering are badly needed in glaucoma. This study will underpin development of a large longitudinal intervention study to determine whether short-term changes in visual function with a neuroprotective agent alter and predict long-term glaucoma progression.

## Study Objectives

*Primary objective*

To determine whether nicotinamide (vitamin B3) supplements in participants with glaucoma leads to short-term improvement in visual function measured using visual fields and the electroretinogram (ERG).

## Study Design

A prospective, randomised, crossover, double-masked, interventional study involving 60 participants with early POAG diagnosed by an ophthalmologist. As there are yet no registered clinical studies on NAM and visual function, the dosage for this study will be based on protocols used NIH-funded clinical trials. An accelerated dose will be used, whereby participants will start a 6-week course at 1.5 g/day followed by 6 weeks at 3 g/day. The dosage is based on that used in mice by Williams et al (2017), which equates to just over 3 g/day human dose (based on the weight of a 70 kg adult), and current clinical trials utilising NAM for improving cognitive function in Alzheimer’s disease (1.5 g twice a day). An accelerated dose method is chosen to ensure participant tolerability to the NAM supplement.

They will be randomised to receive either NAM or placebo for 12 weeks (30 eyes per group). After 12 weeks, participants will crossover, i.e. those taking NAM will switch to placebo and those on placebo with switch to NAM. They will follow the same dose regimen for another 12 weeks. Overall, the study will be 24 weeks in duration.

Participants are seen at baseline, and every 6 weeks afterwards with IOP, blood pressure (BP), ERG, optical coherence tomography (OCT) and visual fields measured in one eye at each visit. Prior to all ERG recordings, pupils will be dilated using 0.5% tropicamide and 2.5% phenylephrine. Participants will be seen every 6 ± 2 weeks after the baseline visit. At each visit, participants are asked to bring in their bottle of remaining tablets for pill counting and the same tests will be undertaken (IOP, ERG, OCT, visual fields).

## Eligibility criteria

**Inclusion criteria** include participants who are over 18 years of age, diagnosed and treated for glaucoma, and best-corrected visual acuity (BCVA) of at least 6/18. Participants are required to have performed a reliable visual field (SAP) in the last 6 months, “reliable” being where all reliability indices are < 33%. If both eyes in a participant are eligible for the study, one eye will be randomly chosen as the study eye.

**Exclusion criteria** for NAM supplementation include those who: are currently or intending to be pregnant or breast-feeding during the study, are unwilling to abstain from other supplements containing vitamin B during the study, have a history of severe allergies or allergic reaction to NAM or niacin, have been diagnosed with cancer in the last 5 years (except treated basal or squamous cell carcinoma), have a history of liver disease, who cannot commit to 6-week follow up visits or cannot provide informed consent. Ophthalmic criteria include eyes with a history of intraocular surgery in the past 6 months (uncomplicated cataract surgery within the last 3 months) and systemic or ocular diseases that are known to affect retinal function (e.g. age-related macular degeneration, demyelinating diseases, diabetic retinopathy).

## Procedures

*Vitamin B3 supplementation*

Translating a preclinical study to the clinic has many difficulties. One here involves the appropriate dosage of NAM. NAM dosage will be based on two current clinical trials, a NIH-funded Phase 3 clinical trial for chronic kidney disease (NCT02258074) using 1.5 g/day and a Phase 2 trial for Alzheimer’s disease (NCT03061474) using 3 g/day.

Both the participant and research coordinator will be masked. An associate researcher will be unmasked, and thus will dispense the required intervention (NAM or placebo) and provide dosage instructions to the participant. Prior to all ERG recordings, pupils will be dilated using 0.5% tropicamide and 2.5% phenylephrine. Participants will be seen every 6 ± 2 weeks after the baseline visit. At each visit, participants are asked to bring in their bottle of remaining tablets for pill counting and the same tests will be undertaken (IOP, ERG, OCT, visual fields).

Though all published clinical studies have not reported any differences in serious adverse events between groups taking NAM or placebo20, 27, it is still possible that side effects may occur. Participants will be informed of potential side effects of taking NAM. These include: nausea (< 1.5%), flushing (< 1.5%), heartburn (< 1.6%), other GI symptoms (< 0.8%), headache (< 0.5%) and fatigue (< 0.4%)27. All participants (regardless of taking NAM or placebo) will be asked to report any side effects they experience via phone call or e-mail when it occurs and will also be asked about side effects at each follow-up visit.

*Randomisation procedure*

Participants were randomised 1:1 with randomly selected block sizes of 4, 6 and 8 using a computer-generated list by the study coordinator to the intervention in either the first or second study period. Participants will be randomly assigned an unmarked bottle of either NAM (Insolar®, Blackmores) or placebo sugar pill (n = 30 per group) and instructed to take it once daily for 6 weeks. After 6 weeks, participants on NAM will move to 3 g/day (1.5 g twice a day) for a further 6 weeks. Participants on placebo will move to twice daily for 6 weeks. After 12 weeks, participants will crossover, to receive the other treatment (either NAM or placebo) for a further 12 weeks using the same dosing regimen.

*Response variables to be measured and measurement methods*

At the baseline visit, we will obtain informed consent and a detailed medical/ophthalmic history. Baseline measurement of visual acuity, intraocular pressure (ICare Pro tonometer, ICare Finland Oy, Vantaa, Finland) and BP using an automated BP monitor will be performed. To measure visual function, a visual field (Humphrey Field Analyser, Carl Zeiss Meditec AG, Jena, Germany) will be obtained in 1 eye and the ERG will be recorded in 1 eye (RETeval®, LKC Technologies, MA, USA). This will use both spatial (visual field) and objective (ERG) measures to assess participants for improvement in the function of nerve cells in the eye. Scans of the retina will be taken using spectral domain optical coherence tomography (OCT).

*Participant compliance*

Whilst pill counting is not the most reliable method to measure compliance, there is yet to be a consensus on the best method to use. Despite these precautionary measures, it is expected that compliance will vary within the cohort and over the study period. Therefore, a minimum 70% compliance rate will be deemed acceptable, which approximately equates to forgetting to take the tablets twice a week.

*Potential sources of bias*

The pool of participants recruited for participants will all have similar baseline characteristics: diagnosed glaucoma. Once recruited, participants will be randomly allocated to treatment or control, where both the participant and researcher dispensing to them will be masked. Data analysis will be masked such that performance and detection bias is reduced.

*Potential confounding factors*

Participants will be carefully screened at selection to ensure they meet all the eligibility criteria. Potential confounding factors include different patient demographics: age, gender, weight, ethnicity. To control for this, a mixture of patient demographics will be included, and with our larger sample size and randomisation process, we will try to limit the effect of such confounders. In light of this, identified confounders can also be controlled for by analyzing for an association between the treatment and confounding factor via stratified analysis or multi-variable regression analysis.

*Primary outcome measures*

The primary outcome measure will be short-term changes in function (ERG and visual fields) over 12 weeks of taking NAM. Specifically, changes to a-wave and b-wave amplitudes (μV) and latency (ms), and changes to PhNR amplitude and PhNR/b-wave ratio as a function of stimulus intensity. Visual fields will be analysed as per literature32. Alterations to RNFL thickness on SD-OCT and changes to IOP and ocular perfusion pressure (the balance between BP and IOP) will also be considered.

*Anticipated outcomes*

It is anticipated that the photopic ERG will successfully capture greater improvement in retinal function with NAM intervention compared to those on placebo. This change may also be visible in the visual field of patients who respond positively. Similar to our previous work investigating short-term changes in visual function with glaucoma treatment where ~40% of the cohort showed sustained functional gains, it is anticipated that a sub-group will demonstrate functional recovery. This will likely occur with minimal structural changes to RNFL thickness as measured using SD-OCT.

*Withdrawal from study/loss to follow-up*

The investigator may withdraw a participant from the study treatment if the participant:

* Is in violation of the protocol
* Experiences a serious or intolerable adverse event
* Develops, during the course of the study, symptoms or conditions listed in the exclusion criteria
* The participant wishes to withdraw themselves from treatment

The investigator will also withdraw all participants from the study treatment if the study is terminated. Individuals who discontinue the study treatment will be encouraged to continue in the study and complete the evaluations. Participants are free to withdraw from the study at any time upon their request or the request of their legally acceptable representative.

When a participant withdraws from the study, the reasons for withdrawal will be recorded by the investigator. Whenever possible, all participants who withdraw from the study prematurely will continue to undergo scheduled visits for study assessments (follow‐up). Participants who discontinue the study treatment will also be encouraged to complete the study visits and evaluations. Participants who fail to return for study assessments will be contacted by the research team in an attempt to have them comply with the protocol, by two documented phone calls and one letter.

# 

# Data Management

## *Data collection*

Data from this study will be recorded onto source documents and transcribed on to case report forms (CRFs). Other source data relevant to the participant’s general medical care will be documented in and/or taken from the patient chart and laboratory records. Data from the CRFs will then be entered into the database.

Completed CRFs will be checked for completeness and accuracy by one of the investigators. Original case report forms will be used when entering information into the computer database. The database will be checked against the case report forms for accuracy. No investigation of the data will begin until an accurate database has been assured.

## *Data storage*

Participants will be assigned a study identification (ID) number for entry onto the CRF and into the database. All CRFs and study files will be stored in a locked filing cabinet in the Centre for Eye Research Australia. The study database will be stored on a secure server at the Centre for Eye research Australia, to which only the study team will have access to.

## *Study record retention*

Study records will be kept for 15 years after the completion of the trial, in accordance with the requirements of the Therapeutic Goods Administration and Health Privacy Principals. Records will be stored in a locked filing cabinet in the Centre for Eye Research Australia and the database will be stored on a secure server at the Centre for Eye Research Australia to which only the study team will have access to. At the end of the 15 year period the records will be shredded and disposed of in a confidential manner, and computer files will be securely deleted.

# 

# Administration

## *Confidentiality*

Participant confidentiality is strictly held in trust by the participating investigators, research staff, and the sponsoring institution and their agents. The study protocol, documentation, data and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party, without prior written approval of the sponsoring institution (CERA). Authorized representatives of the sponsoring institution may inspect all documents and records required to be maintained by the Investigator, including but not limited to, medical records (office, clinic or hospital) and pharmacy records for the participants in this study. The clinical study site will permit access to such records. All laboratory specimens, evaluation forms, reports and other records that leave the site will be identified only by the Participant Identification Number (ID) to maintain participant confidentiality. Clinical information will not be released without written permission of the participant, except as necessary for monitoring by the HREC or regulatory agencies.

## *Independent HREC approval*

This protocol and the informed consent document and any subsequent modifications will be reviewed and approved by the human research ethics committee (HREC). A letter of protocol approval by HREC will be obtained prior to the commencement of the study, as well as approval for other study documents subject to HREC review.

## *Modifications of the protocol*

This study will be conducted in compliance with the current version of the protocol. Any change to the protocol document or Participant Informed Consent Form that affects the scientific intent, study design, participant safety, or may affect a participants’ willingness to continue participation in the study is considered an amendment, and therefore will be written and filed as an amendment to this protocol and/or informed consent form. All such amendments will be submitted to the HREC, for approval prior to becoming effective.

## *Protocol deviations*

All protocol deviations will be recorded in the patient record (source document) and on the CRF and will be reported to the Principal Investigators. Protocol deviations will be assessed for significance by the Principal Investigator. Those deviations deemed to have a potential impact on the integrity of the study results, patient safety or the ethical acceptability of the trial will be reported to the HREC within two weeks.

## *Participant reimbursement*

No participant reimbursement will be made for this project.

## *Financial disclosure and conflicts of interest*

None of the investigators on this study have any disclosures or conflicts of interest.

## *Use of data and publications policy*

The principal investigators hold primary responsibility for the data and publication of data. The data will be submitted for publication in a peer reviewed journal within 18 months of the completion of the trial. Information may not be used or passed onto a third party without the approval of the principal investigator.